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Angiotensin II Type 2 Receptors and Cardiac Hypertrophy
in Women With Hypertrophic Cardiomyopathy
Jaap Deinum, Jeanette M.G. van Gool, Marcel J.M. Kofflard, Folkert J. ten Cate, A.H. Jan Danser
Abstract—The development of left ventricular hypertrophy in subjects with hypertrophic cardiomyopathy (HCM) is
variable, suggesting a role for modifying factors such as angiotensin II. Angiotensin II mediates both trophic and
antitrophic effects, via angiotensin II type 1 (AT1-R) and angiotensin II type 2 (AT2-R) receptors, respectively. Here we
investigated the effect of the AT2-R gene A/C3123 polymorphism, located in the 3 untranslated region of exon 3, on left
ventricular mass index (LVMI) in 103 genetically independent subjects with HCM (age, 12 to 81 years). LVMI and
interventricular septum thickness were determined by 2D echocardiography. Extent of hypertrophy was quantified by
a point score (Wigle score). Plasma prorenin, renin, and ACE were determined by immunoradiometric or fluorometric
assays, and genotyping was performed by polymerase chain reaction. In men, no associations between AT2-R genotype
and any of the measured parameters were observed, whereas in women, LVMI decreased with the number of C alleles
(21119, 20118, and 15210 g/m2 in women with the AA, AC, and CC genotype, respectively; P0.015). Similar
C allele–related decreases in women were observed for interventricular septum thickness (P0.13), Wigle score
(P0.05), plasma renin (P0.03), and plasma prorenin (P0.26). Multiple regression analysis revealed that the AT2-R
C allele–related effect on LVMI (30.711.1, P0.010) occurred independently of plasma renin, the AT1-R gene
A/C1166 polymorphism, or the ACE gene I/D polymorphism. In conclusion, AT2-Rs modulate cardiac hypertrophy in
women with HCM, independently of the circulating renin-angiotensin system. These data support the contention that
AT2-Rs mediate antitrophic effects in humans. (Hypertension. 2001;38:1278-1281.)
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Hypertrophic cardiomyopathy (HCM) is characterized byidiopathic myocardial hypertrophy. It often occurs as an
autosomal dominant disorder, but sporadic cases exist. Mu-
tations in 8 different genes, all coding for sarcomeric pro-
teins, have been identified in patients with HCM.1 Patients
vary considerably by phenotype, even if they have identical
causative genotypes. This has led to the idea that trophic and
mitotic factors modify the clinical manifestations of HCM.2
One of these factors is angiotensin (Ang) II. Ang II is
generated by ACE from Ang I, which is formed by renin from
angiotensinogen. Angiotensin production in the heart depends
on kidney-derived renin and/or prorenin.3,4 Both are taken up
from the circulation, either through diffusion into the cardiac
interstitium or by binding to cardiac cells, and prorenin is
activated to renin in cardiac cells.5,6 The extent of hypertro-
phy in subjects with HCM is associated with the ACE I/D
polymorphism and the angiotensinogen M235T polymor-
phism,7,8 although the association may depend on the under-
lying disease gene mutation.9 Moreover, the Ang II type 1
receptor (AT1-R) A/C1166 polymorphism also modulates the
phenotypic expression of hypertrophy in subjects with
HCM.10 AT1-Rs mediate most, if not all, of the known effects
of Ang II, including vasoconstriction and growth stimulation.
Taken together, these data support the concept of Ang II
modifying cardiac hypertrophy in HCM.
In addition to its effects mediated via AT1-Rs, Ang II also
stimulates Ang II type 2 receptors (AT2-Rs). Although
AT2-Rs are upregulated in the human heart under pathologi-
cal conditions,11,12 their effects in man are currently un-
known. Animal studies suggest that AT2-R stimulation may
oppose AT1-R–mediated effects, ie, may result in vasodila-
tion and growth inhibition.13–15 AT2-R stimulation will occur
in patients during treatment with AT1-R antagonists, because
the latter drugs increase the levels of Ang II.
In the present study, we set out to study the role of AT2-Rs
in man by investigating the association between a poly-
morphism in the 3 untranslated region of exon 3 (A/C3123) of
the X chromosome–located AT2-R gene16 and the extent of
cardiac hypertrophy in 103 HCM patients.
Methods
Patients
One hundred sixteen patients with HCM (age, 21 to 81 years)
visiting the HCM Clinic at the Academic Hospital Dijkzigt between
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1994 and 1997 for a routine follow-up were included. HCM had been
diagnosed on the basis of echocardiographic criteria showing a
nondilated, hypertrophied left ventricle (any wall thickness
15 mm) in the absence of known causes of left ventricular
hypertrophy.17 Patients using ACE inhibitors (n7) were excluded
from the study because of interference with the ACE measurement.
Of the remaining 109 subjects, 41 had a sporadic form of HCM and
50 had at least one other affected first-degree family member. The
family history of HCM was unknown in 18 patients. To avoid
potential bias introduced by the presence of genetically dependent
samples (relatives), we randomly selected 1 patient per family. One
patient was excluded because he had Klinefelter’s syndrome (XXY
genotype). This resulted in a final cohort of 103 genetically inde-
pendent patients, of whom 30 were receiving a -adrenergic antag-
onist, 44 a calcium-channel blocker, and 8 a diuretic. The study was
approved by the internal review board, and patients gave informed
consent.
Echocardiographic Methods
Two-dimensional echocardiography was performed with commer-
cially available equipment (Toshiba Sonolayer). Images were rec-
orded on videotape for offline analysis by 2 physicians who were
blinded to the genotyping results. Interventricular septal thickness
and left ventricular mass (LVM) were determined as described
before.10 LVM was indexed (LVMI) to body surface area.
Peak left ventricular outflow tract gradient at rest was estimated
using the modified Bernoulli equation.10 Because echocardiographic
measurement of LVMI may not truly reflect the extent of hypertro-
phy and the involvement (or lack thereof) of the distal (apical) half
of the septum or lateral wall, the extent of hypertrophy was also
assessed by a semiquantitative point score (range, 0 to 10) method
developed by Wigle et al.18
Biochemical Measurements
Prorenin and renin were quantified in peripheral venous blood using
an immunoradiometric assay kit (Nichols Institute).19 Renin and
prorenin are expressed as mU/L, using the human kidney renin
standard MRC 68/356 as a reference. ACE activity was measured
with a commercial kit (ACE Color).20
Genetic Analysis
Peripheral leukocytes were used to isolate genomic DNA in H2O
using the QIAamp Bloodkit (QIAGEN Inc). The ACE I/D poly-
morphism and the AT1-R A/C1166 polymorphism were determined as
described before.10 The AT2-R A/C3123 polymorphism, an AluI
restriction fragment length polymorphism, was determined accord-
ing to Katsuya et al.16
Statistical Analysis
Data are expressed as meanSEM. Analysis was performed with the
SPSS 9.0 statistical package. Hardy-Weinberg equilibrium was
tested by 2 test. Univariate and multiple regression analyses were
conducted to determine the percentage of explained variance in
LVMI that is accounted for by the genotypes of the candidate
modifier genes and other variables. In the multiple regression
analysis, the renin-angiotensin system gene polymorphisms, age,
peak left ventricular outflow tract gradient, and renin concentration
were tested as independent variables. Prorenin and ACE were
excluded from this analysis because of their high correlations with
renin (r0.680, P0.001) and ACE genotype (r0.389, P0.003),
respectively.
Results
Table 1 lists the characteristics of the HCM patients by AT2-R
genotype. Genotype frequencies were in agreement with
Hardy-Weinberg equilibrium. The percentage of patients
taking -adrenergic antagonists, calcium channel blockers, or
diuretics did not differ between the various groups (data not
shown). In men, no genotype-related differences were ob-
served with regard to any of the measured parameters.
Similarly, in women no relationship between AT2-R genotype
and age, body surface area, or plasma ACE was observed.
However, LVMI, Wigle score, and plasma renin in women
decreased in parallel with the number of C alleles. Peak left
ventricular outflow tract gradient was higher in women
carrying the C allele. Univariate regression analysis showed
that AT2-R genotype accounted for 10.5%, 17.8%, 8.8%, and
12.9% of the variability of interventricular septal thickness
(r0.32; P0.044), LVMI (r0.42; P0.007), plasma renin
(r0.30; P0.063), and peak left ventricular outflow tract
gradient (r0.36, P0.023), respectively.
Subdivision of men and women by both AT1-R and AT2-R
genotypes (Table 2), to further investigate the previously
described AT1-R C allele–related effect on LVMI, revealed
that the latter effect was restricted to male carriers of the
AT2-R A allele. In women, using 2-factor ANOVA, no
interaction could be demonstrated between the AT1-R C allele
and the AT2-R C allele with regard to LVMI.
Multiple regression analysis (Table 3) showed that age,
AT2-R genotype, and peak left ventricular outflow tract
TABLE 1. Characteristics of HCM Patients According to AT2-R Genotype
Parameter
Men AT2-R Genotype Women AT2-R Genotype
A
(n31)
C
(n32)
P
(t test)
AA
(n8)
AC
(n15)
CC
(n17)
P
(ANOVA)
Age, y 503 432 0.07 436 484 524 0.47
Body surface area, m2 1.970.02 1.920.02 0.12 1.730.05 1.640.04 1.710.04 0.38
IVS, mm 21.70.8 21.80.9 0.93 25.51.5 23.81.6 21.01.2 0.13
LVMI, g/m2 17010 18210 0.39 21119 20118 15210 0.015
Wigle score (1–10) 6.40.4 6.50.4 0.88 8.00.5 7.30.5 5.60.7 0.05
Gradient, mm Hg 36.67.1 46.87.1 0.31 20.411.4 62.511.2 66.810.0 0.03
Prorenin, mU/L 22241 19121 0.49 25883 18341 15216 0.26
Renin, mU/L 28.16.2 23.72.1 0.64 33.29.0 15.92.7 18.02.9 0.03
ACE, U/L 10.10.5 10.80.6 0.40 9.70.4 8.90.5 9.40.8 0.58
Values are meanSEM. IVS indicates interventricular septum thickness; Gradient, peak left ventricular outflow tract gradient.
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gradient, but not ACE genotype, AT1-R genotype, or plasma
renin, were significant predictors of LVMI in women.
Discussion
The present study shows that the AT2-R genotype, in addition
to the AT1-R genotype,10 modulates the magnitude of LVMI
in HCM patients. To our knowledge, these data are the first to
demonstrate an AT2-R–related effect on growth in the dis-
eased human heart. Interestingly, the Ang II–mediated effects
on LVMI appear to be the result of a balance between AT1-Rs
and AT2-Rs, in a gender-specific manner, in that the AT1-R C
allele–related effect is observed in men carrying the AT2-R A
allele only, whereas the AT2-R C allele–related effect is
observed in women only, irrespective of their AT1-R geno-
type. The concept of the net effect of Ang II being the result
of the balance between AT1-Rs and AT2-Rs, AT2-Rs opposing
the growth-stimulatory effects of AT1-Rs, originates from
studies in whole animals21,22 and isolated cells.14
The polymorphic markers that we tested in the AT1-R and
AT2-R genes, respectively, are located in untranslated re-
gions. Consequently, their association with LVMI must be
explained by a linkage disequilibrium with a functional
variant of the 2 genes. Both receptors are expressed in the
heart, with AT1-Rs predominating under normal condi-
tions.11,12 Initially, it was thought that AT2-Rs are widely
expressed in the fetal heart and disappear after birth, to return
only under pathological conditions.23 More recent studies in
adult animals, however, have shown that this may not be
true.24,25 In cardiomyopathic hamsters, AT2-Rs exert an anti–
AT1-R action on the progression of interstitial fibrosis during
cardiac remodelling, by inhibiting both fibrillar collagen
metabolism and growth of cardiac fibroblasts,21 whereas in
the infarcted rat heart, AT2-R blockade abolishes the benefi-
cial effects of AT1-R blockade.22 In the line of these animal
data and the findings of the present study, it is logical to
assume that AT2-R stimulation in HCM protects against left
ventricular hypertrophy, particularly in women with the CC
phenotype.
The gender-specificity of the association of the AT1-R and
AT2-R genotypes with LVMI is not readily explained. It may
relate to the fact that the AT2-R is located on the
X-chromosome and thus is present twice in women only. The
AT2-R promoter region, unlike the angiotensinogen promoter
region, does not contain estrogen-responsive elements, which
suggests that if estrogens play a role in the development of
left ventricular hypertrophy through AT2-Rs, a third factor is
involved, eg, an estrogen-dependent transcription factor. One
may argue that the estrogen-induced higher angiotensinogen
levels in women, via increased cardiac Ang II generation,
have resulted in more intense AT2-R stimulation. However,
the lower plasma renin levels in women do not support this
possibility.26
The present study may be important from a pharmacother-
apeutic point of view. If AT1-R stimulation is indeed partly
responsible for the increased LVM in subjects with HCM, the
use of ACE inhibitors or AT1-R antagonists in this disease
might be reconsidered. Both are currently not widely used in
HCM, although they are very effective in regressing and
preventing ventricular hypertrophy in hypertension and after
myocardial infarction. Prevention of hypertrophy in HCM is
desirable in view of the increased risk of sudden death with
higher LVM in subjects with HCM.27 The antihypertrophic
effect of AT2-Rs, based on the current and previous data,
raises the possibility that AT1-R antagonists should be pre-
ferred above ACE inhibitors, because the former drugs,
unlike ACE inhibitors, will result in AT2-R stimulation. In
support of this concept, Lim et al28 recently demonstrated that
AT1-R blockade reverses myocardial fibrosis in a transgenic
mouse model of human HCM.
In view of our present findings, one may also speculate on
the role of AT2-R genotypes in other hypertrophic conditions
like hypertensive left ventricular hypertrophy and postinfarc-
tion remodelling. Schmieder et al29 studied the A/G1675 variant
of the AT2-R gene in 120 young males with normal or mildly
elevated blood pressure and found LVMI to be higher in
hypertensives with the A allele than in hypertensives with the
G allele. It would be of interest to repeat this study in a larger
population and preferably also in women.
Finally, the plasma levels of renin were partly determined
by the AT2-R genotype in women, and a similar trend was
observed for the plasma levels of prorenin. Plasma renin
however did not contribute independently to LVMI. These
findings suggest that AT2-Rs, like AT1-Rs, affect the plasma
levels of renin, but that at the same time cardiac Ang II
generation (and thus cardiac AT2-R stimulation) does not
correlate directly with plasma renin levels. The latter might
be explained on the basis of differences in the cardiac uptake
of circulating renin, as well as differences in the uptake and
local activation of circulating prorenin.5,6 The decrease of
TABLE 2. LVMI (g/m2) According to AT1-R and AT2-R Genotype
AT2-R Genotype
AT1-R Genotype
AA ACCC
Men
A 1435 (n17) 20217 (n14)
C 18420 (n14) 18011 (n18)
Women
AA 20731 (n5) 2164 (n3)
AC 19624 (n7) 20527 (n8)
CC 15511 (n13) 14221 (n4)
Values are meanSEM.
In men, LVMI variation is explained for 6.2% (P0.04) by the AT1-R
genotype. In women, LVMI variation is explained for 18.5% (P0.03) by the
AT2-R genotype.
TABLE 3. Multiple Regression Analysis of Factors With
Potential Effect on LVMI in Women
Parameter  SEM P
Age, y 1.794 0.488 0.001
ACE genotype, No. of D alleles 9.837 11.529 0.400
AT1-R genotype, No. of C alleles 5.862 10.696 0.587
AT2-R genotype, No. of C alleles 30.691 11.148 0.010
Renin, mU/L 0.065 0.488 0.895
Gradient, mm Hg 0.445 0.180 0.019
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LVMI with age, and its increase with peak left ventricular
outflow tract gradient have been described before.10,30
In summary, this paper suggests that the variability and/or
extent of cardiac hypertrophy in HCM patients is partly
determined by the balance between stimulation of AT1-Rs
and AT2-Rs, with different effects in men and women. This
may have therapeutic consequences for the prevention of
hypertrophy in these patients, which may be important in
view of the association of hypertrophy with sudden death in
HCM.
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